Inflammatory and immune diseases arise due to aggressive inflammation or defects in the regulation of inflammatory pathways and result in tissue damage and dysfunction. Drug treatment regimens used to treat these diseases are often ineffective due to the complex pathogenesis and the inability to regulate the numerous signaling pathways involved in inflammatory responses and tissue healing. Mesenchymal stem cells (MSCs) offer a potent cell therapy for the treatment of inflammatory and immune disorders due to their ability to regulate complex inflammatory responses, largely through paracrine mechanisms by secreting various cytokines. MSC secreted paracrine factors not only suppress pro-inflammatory responses but also promote endogenous anti-inflammatory cell phenotypes and therefore, have the potential to regulate the multiple signaling pathways and cell types that contribute to the complex pathogenesis of inflammatory and immune diseases. However, lack of a robust therapeutic response to MSCs is observed in disease models, in part due to inconsistent cell numbers at sites of inflammation. Transplantation of MSC spheroids, which increases retention of cells at transplant sites, may offer a means of improving MSC-based therapies for inflammatory diseases. Additionally, MSC immunomodulation can be influenced by the cellular microenvironment, such as the presence of inflammatory cytokines, therefore manipulating physical and chemical elements of the MSC microenvironment may serve as a novel and simple means of enhancing MSC secretion of immunomodulatory paracrine factors. Therefore, the primary objective of this grant application is to regulate human MSC (hMSC) immunomodulation and paracrine secretion through the engineering of transplantable 3D stem cell microenvironments to enhance the efficacy of hMSC-based therapies for the treatment of inflammatory diseases. The central hypothesis of this application is that presentation of cytokines within 3D hMSC aggregates will enhance paracrine secretion to suppress inflammatory responses and promote endogenous anti- inflammatory phenotypes in an acute animal model of inflammatory bowel disease (IBD). This application is significant because it examines the ability to engineer the physical and biochemical elements of 3D MSC microenvironments in order to direct MSC paracrine factor secretion and enhance immunomodulatory capability in vivo. This application is innovative because these results will establish a novel approach for engineering the MSC microenvironment to produce a therapeutically relevant cell population in vivo that can be used to combat a variety of different inflammatory and immune diseases.

Public Health Relevance

Mesenchymal stem cells are inherently capable of secreting factors that can reduce inflammatory responses and modulate host immune cell responses. This application seeks to engineer transplantable aggregates of human mesenchymal stem cells as a novel means to enhance their immunomodulatory and anti-inflammatory properties to combat inflammatory disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AI109499-03
Application #
8892066
Study Section
Biomaterials and Biointerfaces Study Section (BMBI)
Program Officer
Rothermel, Annette L
Project Start
2014-08-01
Project End
2017-07-31
Budget Start
2015-08-01
Budget End
2017-07-31
Support Year
3
Fiscal Year
2015
Total Cost
Indirect Cost
Name
J. David Gladstone Institutes
Department
Type
DUNS #
099992430
City
San Francisco
State
CA
Country
United States
Zip Code
94158
Zimmermann, Joshua A; Hettiaratchi, Marian H; McDevitt, Todd C (2017) Enhanced Immunosuppression of T Cells by Sustained Presentation of Bioactive Interferon-? Within Three-Dimensional Mesenchymal Stem Cell Constructs. Stem Cells Transl Med 6:223-237